Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. (AVTX) reported that its Chief Financial Officer, Christopher Ryan Sullivan, exercised stock options and sold common shares in mid-August 2026. He exercised options to acquire a total of 71,852 shares of common stock at an exercise price of $9.88 per share on August 17 and 18, 2026. Over the same two days, he sold 72,725 shares of common stock in open-market transactions at per-share prices reported around $19.85–$20.05, with specific trades occurring within disclosed ranges. The options exercised were part of grants expiring in 2034 and vesting 25% on March 28, 2025 and monthly thereafter. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.
Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.
Avalo Therapeutics, Inc. (AVTX) officer Christopher Ryan Sullivan has filed a notice under Rule 144 indicating an intent to sell up to 31,031 shares of common stock through Morgan Stanley Smith Barney. The shares relate to option exercises under a registered plan, including blocks of 25,124 and 5,907 shares for services rendered, with a proposed sale date of 08/18/2026. In the prior three months, Sullivan sold 3,749 shares for proceeds of $74,762.10.
AVTX insider Mittie Doyle notified an intention to sell 5,037 shares of common stock on 08/17/2026, tied to an exercise of stock options, with a referenced value of $98,674.83. The notice also lists recent Rule 10b5-1 sales of AVTX common stock over the prior three months with specified share counts and dollar amounts.
A person associated with AVTX has filed a notice of intent to sell common stock. The planned sale covers 3,749 shares of AVTX common stock, with an indicated aggregate market value of 74,762.10, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 17, 2026 on the NASDAQ market.
The shares come from multiple sources, including 2,876 shares acquired via an exercise of options under a registered plan on August 17, 2026 and several smaller lots (such as 450 shares and 417 shares) purchased through an Employee Stock Purchase Plan between 2020 and 2025.
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Avalo Therapeutics, Inc.
As of June 30, 2026, the reporting persons may be deemed to beneficially own 1,862,250 shares of Avalo Therapeutics common stock, representing 3.54% of the outstanding class. All reported shares are held by funds and separately managed accounts controlled by Nantahala, with the reporting persons having shared voting and dispositive power over these shares and no sole voting or dispositive power. Each of Harkey and Mack files as a control person in respect of shares beneficially owned by Nantahala, which is described as an investment adviser.
Caligan Partners LP and David Johnson report beneficial ownership of Avalo Therapeutics, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 3,163,866 shares of common stock, representing 5.9% of the class, based on 53,629,989 shares outstanding as of August 3, 2026.
The reporting persons have shared voting and dispositive power over all 3,163,866 shares and no sole voting or dispositive power. The shares are held by certain funds and accounts for which Caligan serves indirectly as investment manager, with David Johnson as Managing Partner of Caligan and Managing Member of its general partner.
RA Capital Management, L.P. and affiliated entities report beneficial ownership of 3,483,099 shares of Avalo Therapeutics, Inc. common stock as of June 30, 2026, representing 6.3% of the class. The holding consists of 1,000,000 common shares directly owned by RA Capital Healthcare Fund, L.P. and Series C preferred stock convertible into 2,483,099 common shares.
The ownership percentage is calculated based on 52,900,692 common shares outstanding plus the 2,483,099 shares issuable upon conversion of the preferred shares. Voting and dispositive power over the Fund’s holdings has been delegated to RA Capital, and the Fund disclaims beneficial ownership for Section 13(d) purposes. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners under Section 13(d) but each disclaims beneficial ownership except for determining reporting obligations.
Avalo Therapeutics, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert reporting aggregated holdings in Avalo’s common stock. As of June 30, 2026, these reporting persons collectively beneficially owned 2,801,545 shares of common stock, including shares issuable upon conversion of preferred stock, representing approximately 5.3% of the outstanding common stock.
The group holds 726 shares of Series C Non-Voting Convertible Preferred Stock, initially convertible into an aggregate of 726,000 common shares, subject to a 9.99% Beneficial Ownership Limitation, which did not restrict conversion at that time. The ownership percentages are based on 52,565,572 common shares outstanding as of May 8, 2026, plus the relevant convertible shares.